COVID-19 Vaccine Regulatory Strategy Evolving With The Pandemic

 
• By Derrick Gingery

AstraZeneca and Novavax have not filed EUAs for their vaccines, and they never might. The pathway remains viable in the short-term, but as BLAs are approved and supplies are no longer short, the window may close.

Vaccinating the globe against COVID-19
FDA emergency use authorization of the AstraZeneca and Novavax COVID-19 vaccines could be more beneficial for other countries than the US. • Source: Alamy

More from Vaccines

More from Pink Sheet